

Concept Paper Form

Provisional Paper Title: Association of early-life blood pressure exposures with mid-life brain health
Proposing Author: Dr Scott T Chiesa
Author's Email: s.chiesa@ucl.ac.uk
P.I. Sponsors: Professors Terrie Moffitt, Avshalom Caspi, and Ahmad Hariri
Today's Date: 10/28/2021

Please describe your proposal in 2-3 pages with sufficient detail for helpful review.

Objective of the study:

Nearly 50 million people currently live with dementia worldwide, and this figure is expected to triple by 2050(1). Despite decades of research, trials of pharmacological treatments for the condition have met with almost universal failure(2). While the reasons for these failures are still not fully understood, they may be explained by the growing appreciation that dementia represents the end result of a long preclinical phase involving multiple pathophysiological processes and overlapping disease states. Recent years have seen a growing recognition that many of these pathophysiological processes are common to another of the world's leading causes of premature mortality – cardiovascular disease (CVD) – raising the possibility that prevention strategies targeting cardiovascular health may also have a dual benefit for brain health.

In many other fields of medical science (e.g. cardiovascular disease, renal disease, hepatic disease), it has long been known that early and sustained exposure to risk factors may initiate the evolution of a long-term disease process which develops insidiously across the lifespan before culminating in clinical events in older age(3,4). Due in part to extensive research over the last 30 years by my unit at UCL, it is now accepted that the atherosclerotic CVD process starts virtually from birth, with subtle but widespread adverse changes in systemic vascular structure and function detectable even from the first decade of life(5–17). Only in recent years however, has research begun to highlight the critical role that these same factors may play in the development of cognitive impairment and dementia, culminating in a recent report by the Lancet Commission which estimated that >30% of dementias worldwide could be delayed or prevented by targeting a number of common mid-life risk factors with already well-established links to CVD(1).

Curiously, very little attention within the scientific literature has been paid to the potential effect that CVD risk factor exposures in the first 50 years of life have on brain health prior to mid-life, or the subsequent impact that these early subclinical changes may have on later dementia risk. While a limited number of studies in recent years have begun to address this question in various young adult cohorts such as the Cardiovascular Risk in Young Finns (YFS) or Coronary Artery Risk Development in Young Adults (CARDIA) studies(18–22), no study to date has been able to investigate these relationships in a longitudinal birth cohort containing both lifetime exposures to risk factors from childhood and – critically – data on early childhood cognitive function which may confound findings due to neuroselection.

Elevated blood pressure is one of the world's leading causes of CVD, has repeatedly been shown to be a robust mid-life predictor of future dementia, and has previously been demonstrated in this cohort to diverge during adolescence and track across young adulthood. This study therefore aims to investigate potential associations between cumulative exposure to blood pressure over the early decades of life and neuroimaging and cognitive outcomes in mid-life. We hypothesise that increased exposure to high blood pressure over the first 40-50 years of life will result in adverse subclinical changes in brain health which may increase risk of dementia, and that these associations will remain once the potential confounding effect of childhood cognitive function has been considered.

Data analysis methods:

All data analysis will be carried out in the Department of Psychology and Neuroscience at Duke University. Both continuous and categorical blood pressure measures will be used as potential exposures in statistical analyses. For continuous data, individual intercepts and slopes from repeated blood pressure measures will be calculated for each participant using mixed linear models, with trapezoidal integration then used to provide a continuous measure of exposure represented by the area under the curve for each participant. Trajectories of lifetime blood pressure exposure will also be tested as categorical variables using data derived from a previous publication in this cohort (Theodore et al 2015 Hypertension). Multiple linear regression will be used to test for associations between each of these exposures and a range of neuroimaging and cognitive outcomes. Firstly, a BrainAGE metric derived from previous work within this cohort will be used as a marker of overall brain health. In the event that significant associations are found with this novel biomarker, secondary analyses of more specific structural changes measured using MRI (e.g. white matter integrity, WMHs, etc) will be conducted to further explore these relationships. For cognitive outcomes, both continuous and categorical exposures will be tested against adult IQ measured at age 45. Four models will be created for each exposure: Model 1=unadjusted; Model 2=model 1 + adjustments for age and sex; Model 3=model 2 + adjustments for BMI and current blood pressure; and Model 4=model 3 + adjustments for education level and socioeconomic status. In order to test for a potential confounding effect of childhood IQ levels (i.e. neuroselection), two further approaches will be used. Firstly, additional models containing childhood IQ (average of three measures ~ age 10) will be created to assess whether the (hypothesized) independent effect of BP on mid-life outcomes remains/is attenuated/lost following statistical adjustment. Secondly, a secondary analysis employing childhood IQ as the exposure and cumulative exposure to blood pressure across early-life as outcome will be used to test for potential bidirectional relationships between these factors. Finally, if robust independent relationships are found between early-life blood pressure and mid-life outcomes, the use of

genotyping data contained within the cohort may allow the creation of polygenic risk scores for blood pressure which may provide causal inferences to be drawn from our observational findings.

Variables needed at which ages:

Exposures:

Blood pressure measures at ages 7, 11, 18, 26, 32, 38, and 45.

Blood pressure trajectories derived as part of Theodore et al 2015 Hypertension paper (DOI: 10.1161/HYPERTENSIONAHA.115.05831)

Blood pressure PRS constructed according to Vaura et al 2021 Hypertension paper (doi.org/10.1161/HYPERTENSIONAHA.120.16471).

Outcomes:

Neuroimaging (all at age 45) –

BrainAGE

Average cortical thickness, surface area, and fractional anisotropy

Parcel-wise cortical thickness and surface area

Tract-wise white matter integrity assessed via fractional anisotropy

White matter hyperintensity volumes

Subcortical grey matter volumes

Total cortical volume

Cognitive (age 45) –

Wechsler Adult Intelligence Scale - IV

Covariates:

Wechsler Intelligence Scale for Children Revised at ages 7, 9, and 11

Age, sex, BMI, blood pressure, lipids (LDL, HDL), inflammation (hsCRP), glucose at age 45

Highest education level

Socioeconomic status

Weight at birth

Significance of the Study (for theory, research methods or clinical practice):

This study proposal addresses a fundamental gap in our understanding of whether one of the major lifetime risk factors known to increase risk of CVD may also associate with the presence of subclinical brain and cognitive changes in mid-life which are believed to underlie dementia. These findings may ultimately help to shift health policies for brain health to be similar to that of heart health, in which a lifetime approach to healthy lifestyle choices is promoted as the most effective way of extending healthy years lived.

References cited:

1. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Vol. 396, *The Lancet*. 2020. p. 413–46.
2. Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015. *Expert Opin Investig Drugs*. 2017;26(6):735–9.
3. Lloyd-Jones DM, Leip EP, Larson MG, D’agostino RB, Beiser A, Wilson PWF, et al. Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years. *Circulation*. 2006;113(6):791–8.
4. Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, et al. Lifetime Risks of Cardiovascular Disease. *N Engl J Med*. 2012 Jan 26;366(4):321–9.
5. Chiesa ST, Charakida M, McLoughlin E, Nguyen HC, Georgiopoulos G, Motran L, et al. Elevated high-density lipoprotein in adolescents with Type 1 diabetes is associated with endothelial dysfunction in the presence of systemic inflammation. *Eur Heart J*. 2019;40(43):3559–66.
6. Wade KH, Chiesa ST, Hughes AD, Chaturvedi N, Charakida M, Rapala A, et al. Assessing the Causal Role of Body Mass Index on Cardiovascular Health in Young Adults: Mendelian Randomization and Recall-by-Genotype Analyses. *Circulation*. 2018;138.
7. Donald AE, Charakida M, Falaschetti E, Lawlor DA, Halcox JP, Golding J, et al. Determinants of vascular phenotype in a large childhood population: the Avon Longitudinal Study of Parents and Children (ALSPAC). *Eur Heart J*. 2010;31(12):1502–10.
8. Charakida M, Jones A, Falaschetti E, Khan T, Finer N, Sattar N, et al. Childhood obesity and vascular phenotypes: A population study. *J Am Coll Cardiol*. 2012;60(25):2643–50.
9. Falaschetti E, Hingorani AD, Jones A, Charakida M, Finer N, Whincup P, et al. Adiposity and cardiovascular risk factors in a large contemporary population of pre-pubertal children. *Eur Heart J*. 2010;31(24):3063–72.
10. Sletner L, Mahon P, Crozier SR, Inskip HM, Godfrey KM, Chiesa S, et al. Childhood Fat and Lean Mass: Differing Relations to Vascular Structure and Function at Age 8 to 9 Years. *Arterioscler Thromb Vasc Biol*. 2018 Oct;38(10):2528–37.
11. Sletner L, Crozier SR, Inskip HM, Godfrey KM, Mahon P, Chiesa ST, et al. Childhood vascular phenotypes have differing associations with prenatal and postnatal growth. *J Hypertens*. 2021;
12. Dangardt F, Charakida M, Georgiopoulos G, Chiesa ST, Rapala A, Wade KH, et al. Association between fat mass through adolescence and arterial stiffness: a population-based study from The Avon Longitudinal Study of Parents and Children. *Lancet Child Adolesc Heal*. 2019 Jul 1;3(7):474–81.
13. Chiesa ST, Marcovecchio ML, Benitez-Aguirre P, Cameron FJ, Craig ME, Couper JJ, et al. Vascular Effects of ACE (Angiotensin-Converting Enzyme) Inhibitors and Statins in Adolescents with Type 1 Diabetes. *Hypertension*. 2020;76(6):1734–43.
14. Marcovecchio ML, Chiesa ST, Armitage J, Daneman D, Donaghue KC, Jones TW, et al. Renal and Cardiovascular Risk According to Tertiles of Urinary Albumin-to-Creatinine Ratio: The Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT). *Diabetes Care*. 2018;41(9):1963–9.
15. Chiesa ST, Charakida M, Georgiopoulos G, Dangardt F, Wade KH, Rapala A, et al.

- Determinants of Intima-Media Thickness in the Young: The ALSPAC Study. *JACC Cardiovasc Imaging*. 2021;14(2):468–78.
16. Charakida M, Georgiopoulos G, Dangardt F, Chiesa ST, Hughes AD, Rapala A, et al. Early vascular damage from smoking and alcohol in teenage years: The ALSPAC study. *Eur Heart J*. 2019;40(4):345–53.
 17. Jones A, Charakida M, Falaschetti E, Hingorani AD, Finer N, Masi S, et al. Adipose and Height Growth Through Childhood and Blood Pressure Status in a Large Prospective Cohort Study. *Hypertension*. 2012 May 1;59(5):919–25.
 18. Rovio SP, Pahkala K, Nevalainen J, Juonala M, Salo P, Kähönen M, et al. Cardiovascular Risk Factors From Childhood and Midlife Cognitive Performance: The Young Finns Study. *J Am Coll Cardiol*. 2017;69(18):2279–89.
 19. Hakala JO, Pahkala K, Juonala M, Salo P, Kähönen M, Hutri-Kähönen N, et al. Cardiovascular Risk Factor Trajectories Since Childhood and Cognitive Performance in Midlife: The Cardiovascular Risk in Young Finns Study. *Circulation [Internet]*. 2021 [cited 2021 May 18];143(20):1949–61. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33966448>
 20. Suvila K, Lima JAC, Yano Y, Tan ZS, Cheng S, Niiranen TJ. Early-but Not Late-Onset Hypertension Is Related to Midlife Cognitive Function. *Hypertension*. 2021;
 21. Yaffe K, Bahorik AL, Hoang TD, Forrester S, Jacobs DR, Lewis CE, et al. Cardiovascular risk factors and accelerated cognitive decline in midlife: The CARDIA Study. *Neurology*. 2020;95(7):e839–46.
 22. Launer LJ, Lewis CE, Schreiner PJ, Sidney S, Battapady H, Jacobs DR, et al. Vascular factors and multiple measures of early brain health: CARDIA brain MRI study. *PLoS One [Internet]*. 2015 Mar 26 [cited 2021 Apr 12];10(3). Available from: <https://pubmed.ncbi.nlm.nih.gov/25812012/>